Mexicetine drug moa
Mexiletine (note the spelling) is an antiarrhythmic drug. Here's a quick overview before I pull from the medical library:
Quick Answer: Mexiletine is a Class IB antiarrhythmic agent that works by blocking fast voltage-gated sodium (Na+) channels in cardiac and skeletal muscle. It preferentially binds to inactivated sodium channels, reducing the rate of depolarization and suppressing ventricular arrhythmias. It also has use in myotonic disorders.
Searching sources...
Reading File
Finding Sources
Searching the Web
mexiletine mechanism of action sodium channel antiarrhythmic Class IB
Now let me pull the detailed textbook content from Braunwald's and Katzung's:
Reading File
Reading File
Here is a complete, textbook-sourced breakdown of mexiletine's mechanism of action:
Mexiletine - Mechanism of Action
Drug Class
Mexiletine is a Class IB antiarrhythmic agent - a local anesthetic congener of lidocaine with anticonvulsant properties, used for the oral treatment of ventricular arrhythmias.
Core Mechanism: Sodium Channel Blockade
Mexiletine's primary MOA is blocking fast voltage-gated sodium channels (I_Na):
- It inhibits the inward sodium current required for initiation and conduction of cardiac impulses
- It depresses V_max (maximum rate of rise) of phase 0 of the action potential - this is the fast depolarization phase driven by Na+ influx
- Like lidocaine, it preferentially binds inactivated sodium channels (i.e., it is more effective at faster heart rates and in depolarized/ischemic tissue) - this is termed use-dependent (frequency-dependent) block
- Its onset and offset kinetics are rapid (a key feature distinguishing Class IB from IC agents)
Electrophysiologic Effects
| Parameter | Effect |
|---|---|
| Action potential duration (APD) | Shortened - in Purkinje fibers and ventricular muscle |
| Effective refractory period (ERP) | Shortened - primarily in Purkinje fibers |
| Phase 0 V_max | Depressed (I_Na block) |
| Automaticity | Suppressed in Purkinje fibers (not in normal sinus node) |
| AV nodal conduction | Not affected |
| His-Purkinje conduction | Mildly depressed (mainly if already abnormal) |
| QT interval | Not prolonged (unlike Class IA agents); may actually shorten it |
| Atrial muscle | Not significantly affected |
Effect on Ischemic/Hypoxic Tissue
Hypoxia and ischemia potentiate mexiletine's effects - it preferentially affects depolarized tissue, making it particularly useful post-MI when ventricular ectopy arises from partially depolarized, ischemic Purkinje fibers.
Hemodynamic Profile
Mexiletine exerts no major hemodynamic effects on ventricular contractile performance or peripheral resistance - an advantage over many other antiarrhythmics.
Additional MOA: LQT3 / Sodium Channel Gain-of-Function
In Long QT syndrome type 3 (LQT3), a gain-of-function mutation in SCN5A causes persistent (late) inward Na+ current. Mexiletine blocks this late I_Na, shortening QTc by approximately 30-40 ms in LQT3 patients - making it useful as gene-specific therapy for this condition.
Pain & Myotonia MOA
Mexiletine also blocks skeletal muscle sodium channels (Nav1.4), reducing membrane hyperexcitability. This underlies its off-label use in:
- Myotonia (muscle stiffness from prolonged muscle fiber depolarization)
- Neuropathic pain (e.g., diabetic neuropathy) - by dampening ectopic sodium channel activity in injured nerves
Comparison with Class IB Siblings
| Feature | Mexiletine | Lidocaine | Phenytoin |
|---|---|---|---|
| Route | Oral | IV only | Oral/IV |
| Use | Chronic ventricular arrhythmias | Acute ventricular arrhythmias | Digitalis-induced arrhythmias |
| QT effect | Neutral/shorten | Neutral | Neutral |
| Kinetics | Fast onset/offset | Fast onset/offset | Fast onset/offset |
Key Clinical Points
- Indications: Ventricular tachyarrhythmias, LQT3, myotonia, neuropathic pain (off-label)
- Adverse effects: Predominantly neurologic (tremor, dizziness, blurred vision, nystagmus, dysarthria) and GI (nausea, vomiting) - up to 40% require dose adjustment
- Pharmacokinetics: Oral bioavailability near 100%, half-life ~10 hours (17 hours post-MI), therapeutic range 0.5-2 mcg/mL
- Drug interactions: Metabolism increased by phenytoin, phenobarbital, rifampin; reduced by cimetidine
Sources: Braunwald's Heart Disease (Electrophysiologic Actions section); Katzung's Basic and Clinical Pharmacology, 16th ed. (Mexiletine, Subgroup 1B)
This is a shared conversation. Sign in to Orris to start your own chat.